News from IMIM
Researchers from the Molecular Cancer group at the Hospital del Mar Medical Research Institute (IMIM) and doctors from Hospital del Mar, have demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment. The preliminary results of an ongoing clinical trial show that TAK-228, a mTORC1/2 protein inhibitor, can stop the progression of the disease. Four of the seven patients in the trial showed positive results. The trial also involved Hospital de la Santa Creu i Sant Pau in Barcelona, Hospital Universitari Parc Taulí in Sabadell, Clínica Universitaria in Navarre, and Hospital General Universitario in Elche.
The principle behind this drug (developed by the Japanese pharmaceutical Takeda), is the inhibition of the mTORC1/2 protein, commonly present in tumours. This protein plays a key role in the development and spread of tumours. The researchers analysed its effectiveness in the laboratory, in bladder cancer cell lines both in vitro and implanted into mice. They also worked with fresh tissue from the tumours of patients. The novelty is that, at the same time, they designed a clinical trial that is now underway.
"The fact of discovering a new mechanism of action for this mTORC1/2 inhibitor, beyond inhibiting this pathway, in other words, which acts against a molecular target -a specific genetic alteration, allows us to hope for much more than we originally expected", explains Dr. Joaquim Bellmunt, director of the IMIM and principal author of the study.
Hernández A, Rodríguez-Vida A, Juanpere N, Arpí O, Menéndez S, Soria-Jiménez L, Martínez-Fernández A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J*. Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models. Mol Canc Res 2019: (In press).